secwatch / observer
8-K filed October 15, 2024, 7:59 PM ET ticker AXIM CIK 0001514946
other material confidence high sentiment negative materiality 0.80

Change in control at AXIM Biotechnologies; CEO John Huemoeller dies, Catalina Valencia named President

AXIM BIOTECHNOLOGIES, INC.

item 5.01item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catalina Valencia

Series C Director
AXIM · AXIM BIOTECHNOLOGIES, INC.
Effective
2024-10-14
Filed
October 15, 2024, 7:59 PM ET
effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy
Departed

John W. Huemoeller II

President and CEO
AXIM · AXIM BIOTECHNOLOGIES, INC.
Effective
2024-10-09
Successor
Catalina Valencia
Filed
October 15, 2024, 7:59 PM ET
Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness
Departed

John W. Huemoeller II

Series C Director
AXIM · AXIM BIOTECHNOLOGIES, INC.
Effective
2024-10-12
Successor
Catalina Valencia
Filed
October 15, 2024, 7:59 PM ET
On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.
Appointed

Catalina Valencia

President
AXIM · AXIM BIOTECHNOLOGIES, INC.
Effective
2024-10-09
Filed
October 15, 2024, 7:59 PM ET
on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Catalina Valencia was appointed as Series C Director at AXIM BIOTECHNOLOGIES, INC..

Action
appointed
Role
Series C Director
Exact text from the filing
effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John W. Huemoeller II departed as President and CEO at AXIM BIOTECHNOLOGIES, INC..

Action
unable to serve
Role
President and CEO
Exact text from the filing
Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

John W. Huemoeller II departed as Series C Director at AXIM BIOTECHNOLOGIES, INC..

Action
died
Role
Series C Director
Exact text from the filing
On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Catalina Valencia was appointed as President at AXIM BIOTECHNOLOGIES, INC..

Action
appointed
Role
President
Exact text from the filing
on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.
View on SEC.gov

AXIM BIOTECHNOLOGIES, INC. filing history →

Source: SEC EDGAR
accession 0001096906-24-002002
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.